Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

NSE:KREBSBIO

KREBS BIOCHEMICALS & IND

Healthcare › Pharmaceuticals & Biotechnology

₹57.50

at close · 6 Nov 2026

▼ 0.30 (-0.52%)

Get alerts

Latest filings

Fri, 30 OctRevenue rises, but quarterly loss increases from June · Compliance
Thu, 29 OctQ2 revenue rises 39%, but net loss persists at Rs 539.85 lakh · Results
Thu, 29 OctSeptember quarter revenue rises 39%, but loss persists as Vizag unit stays shut · Results

All filings ↓

Ask Nexa about KREBS BIOCHEMICALS & IND

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹27 Cr over the trailing twelve months.

Market Cap

₹124 Cr

P / E (TTM)

—

EV / EBITDA

—

Div Yield

—

Growth

-15.1%▼

Revenue 5y CAGR

PAT — · EBITDA —

Quality

-19.6%·

ROCE (5y median)

ROE n/m · margin -23.0%

Leverage

n/m·

Debt / Equity · negative net worth

Net debt ₹227 Cr

Revenue FY21→FY26

0.4×▼

Margin −18.5 pts

₹54 Cr → ₹24 Cr

Moves on a normal day

1.72%·

Median daily move

Last 268 sessions · the yardstick for filing-day moves

Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures

ROCE#168/177

EBITDA margin#171/178

Revenue growth#34/163

Profit growth#90/157

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths

Negative working-capital cycle — the business is funded by its suppliers

Concerns

Revenue shrinking over 5 years (−15% a year)

Negative returns on capital — −19.6% (5-year median)

#168 of 177 in Pharmaceuticals on the latest reported figures

Negative net worth — liabilities exceed assets by ₹163 Cr (FY26)

Debt-to-equity and return on equity are not meaningful below zero equity

Charts

How has the market priced it — with filings on the timeline?

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Governance

Is the board independent, clean and well-run?

Compliance

Did a company secretary sign off that it's clean?

Audit Report

What the auditor actually said — opinion, key audit matters, CARO clauses.

Earnings Call

What management said — and how it landed.

Investor Presentation

An AI read of the latest deck — verdict, KPIs, key slides and what it promised.

Events

Board meetings and results dates, upcoming and recent.

Reactions

How does the stock move after this company files?

Filings

The full disclosure feed.

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from KREBS BIOCHEMICALS & IND's filed financials and exchange disclosures

What does KREBS BIOCHEMICALS & IND do?

KREBS BIOCHEMICALS & IND is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol KREBSBIO.

Is KREBS BIOCHEMICALS & IND profitable?

No. Over the trailing twelve months KREBS BIOCHEMICALS & IND reported a net loss of ₹13 Cr on revenue of ₹27 Cr.

Does KREBS BIOCHEMICALS & IND pay a dividend?

Not in the latest reported year — KREBS BIOCHEMICALS & IND's dividend payout for FY26 was nil.

Is KREBS BIOCHEMICALS & IND debt-free?

No. It reported borrowings of ₹227 Cr on its 30 Sept 2026 balance sheet, or net debt of ₹227 Cr after cash. Its net worth is negative — liabilities exceed assets by ₹171 Cr, so a debt-to-equity ratio is not meaningful.

How much does the KREBS BIOCHEMICALS & IND share price move in a day?

On a typical session KREBS BIOCHEMICALS & IND moves 1.72% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track KREBS BIOCHEMICALS & IND's announcements?

Every NSE and BSE filing by KREBS BIOCHEMICALS & IND appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.